10,493 reports of this reaction
7.4% of all INFLIXIMAB DYYB reports
#2 most reported adverse reaction
CONDITION AGGRAVATED is the #2 most commonly reported adverse reaction for INFLIXIMAB DYYB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 10,493 FDA adverse event reports linking INFLIXIMAB DYYB to CONDITION AGGRAVATED. This represents approximately 7.4% of all 142,758 adverse event reports for this drug.
Patients taking INFLIXIMAB DYYB who experience condition aggravated should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONDITION AGGRAVATED is moderately reported among INFLIXIMAB DYYB users, representing a notable but not dominant share of adverse events.
In addition to condition aggravated, the following adverse reactions have been reported for INFLIXIMAB DYYB:
The following drugs have also been linked to condition aggravated in FDA adverse event reports:
CONDITION AGGRAVATED has been reported as an adverse event in 10,493 FDA reports for INFLIXIMAB DYYB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONDITION AGGRAVATED accounts for approximately 7.4% of all adverse event reports for INFLIXIMAB DYYB, making it one of the most commonly reported side effect.
If you experience condition aggravated while taking INFLIXIMAB DYYB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.